59.22
price up icon2.09%   1.215
after-market After Hours: 59.22
loading
Praxis Precision Medicines Inc stock is traded at $59.22, with a volume of 689.82K. It is up +2.09% in the last 24 hours and up +36.67% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$58.01
Open:
$58.28
24h Volume:
689.82K
Relative Volume:
2.00
Market Cap:
$1.21B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-6.458
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
+9.97%
1M Performance:
+36.67%
6M Performance:
-23.20%
1Y Performance:
+2.92%
1-Day Range:
Value
$56.66
$61.03
1-Week Range:
Value
$53.88
$61.03
52-Week Range:
Value
$26.70
$91.83

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name
Name
Praxis Precision Medicines Inc
Name
Phone
617-300-8460
Name
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Name
Employee
82
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
PRAX's Discussions on Twitter

Compare PRAX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PRAX
Praxis Precision Medicines Inc
59.22 1.18B 1.77M -123.74M -95.21M -9.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-02-25 Resumed Oppenheimer Outperform
May-07-25 Initiated Chardan Capital Markets Buy
Mar-03-25 Reiterated H.C. Wainwright Buy
Feb-11-25 Initiated Deutsche Bank Buy
Aug-05-24 Initiated Oppenheimer Outperform
Jun-24-24 Initiated Needham Buy
Jun-18-24 Initiated Guggenheim Buy
May-01-24 Initiated Robert W. Baird Outperform
Sep-19-23 Initiated Truist Buy
Jun-06-22 Downgrade Wedbush Outperform → Neutral
Dec-16-21 Initiated H.C. Wainwright Buy
Aug-26-21 Initiated BofA Securities Buy
Apr-26-21 Initiated William Blair Outperform
Nov-11-20 Initiated Wedbush Outperform
Nov-10-20 Initiated Cowen Outperform
Nov-10-20 Initiated Evercore ISI Outperform
Nov-10-20 Initiated Piper Sandler Overweight
View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

pulisher
02:14 AM

What makes Praxis Precision Medicines Inc. stock price move sharplyFast Gains With Reduced Risk - Metal.it

02:14 AM
pulisher
Jul 25, 2025

What analysts say about Praxis Precision Medicines Inc. stock outlookFree Market Volatility Navigation Tips - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Why Praxis Precision Medicines Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser

Jul 25, 2025
pulisher
Jul 25, 2025

Will Praxis Precision Medicines Inc. stock benefit from AI tech trendsPhenomenal capital gains - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Praxis Precision Medicines Inc. Stock Analysis and ForecastTremendous return on equity - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

Is Praxis Precision Medicines Inc. a good long term investmentExceptional profit potential - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 23, 2025

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Praxis Precision Medicines Inc. stock priceConsistent triple-digit returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Praxis Precision Medicines Inc. stockBreakthrough capital growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Major Depressive Disorder Clinical Trials, Companies, - openPR.com

Jul 22, 2025
pulisher
Jul 22, 2025

Does Praxis Precision Medicines Inc. stock pay reliable dividendsShort Squeeze Radar - Newser

Jul 22, 2025
pulisher
Jul 21, 2025

Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright - Defense World

Jul 21, 2025
pulisher
Jul 20, 2025

(PRAX) Trading Report - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 19, 2025

Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation - 富途牛牛

Jul 19, 2025
pulisher
Jul 18, 2025

Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy - Investing.com Nigeria

Jul 18, 2025
pulisher
Jul 18, 2025

Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy By Investing.com - Investing.com South Africa

Jul 18, 2025
pulisher
Jul 18, 2025

PRAX: HC Wainwright & Co. Reiterates Buy Rating with $105 Target - GuruFocus

Jul 18, 2025
pulisher
Jul 17, 2025

Praxis Precision gets FDA breakthrough therapy status for Relutrigine - Seeking Alpha

Jul 17, 2025
pulisher
Jul 17, 2025

FDA grants breakthrough therapy designation to Praxis’ relutrigine for pediatric epilepsy - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Q1 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World

Jul 17, 2025
pulisher
Jul 17, 2025

Praxis Precision Medicines and the Breakthrough Potential of Relutrigine in Rare Epilepsy Therapies: Strategic and Financial Implications of FDA Breakthrough Therapy Designation - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Praxis Says FDA Grants Breakthrough Therapy Designation To Relutrigine For Rare Pediatric Epilepsies - Nasdaq

Jul 17, 2025
pulisher
Jul 17, 2025

FDA grants breakthrough therapy status to Praxis’s relutrigine By Investing.com - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

FDA grants breakthrough therapy status to Praxis’s relutrigine - Investing.com Australia

Jul 17, 2025

Praxis Precision Medicines Inc Stock (PRAX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):